

## The role of FAM107A in prostate carcinoma

**Supplementary Table 1.** The association between the FAM107A expression and the clinicopathologic features

Characters	level	Low expression of FAM107A	High expression of FAM107A	P	test
n		248	247		
T stage (%)	T2	72 (29.3%)	115 (47.5%)	<0.001	exact
	T3	167 (67.9%)	124 (51.2%)		
	T4	7 (2.8%)	3 (1.2%)		
N stage (%)	N0	163 (73.4%)	181 (90.5%)	<0.001	
	N1	59 (26.6%)	19 (9.5%)		
M stage (%)	M0	224 (98.7%)	229 (100.0%)	0.123	exact
	M1	3 (1.3%)	0 (0.0%)		
Gleason score (%)	10	3 (1.2%)	1 (0.4%)	<0.001	exact
	6	12 (4.8%)	33 (13.4%)		
	7	103 (41.5%)	143 (57.9%)		
	8	39 (15.7%)	24 (9.7%)		
	9	91 (36.7%)	46 (18.6%)		
Primary therapy outcome (%)	CR	154 (72.6%)	183 (82.4%)	0.045	
	PD	14 (6.6%)	14 (6.3%)		
	PR	27 (12.7%)	13 (5.9%)		
	SD	17 (8.0%)	12 (5.4%)		
Residual tumor (%)	R0	145 (62.5%)	169 (72.5%)	0.061	exact
	R1	84 (36.2%)	62 (26.6%)		
	R2	3 (1.3%)	2 (0.9%)		
Race (%)	Asian	9 (3.7%)	3 (1.3%)	0.152	
	Black/African American	31 (12.8%)	25 (10.5%)		
	White	202 (83.5%)	210 (88.2%)		
Zone of origin (%)	Central Zone	3 (2.0%)	1 (0.8%)	0.314	exact
	Overlapping/Multiple Zones	76 (50.0%)	50 (41.0%)		
	Peripheral Zone	68 (44.7%)	68 (55.7%)		
	Transition Zone	5 (3.3%)	3 (2.5%)		
TP53 status (%)	Mut	39 (15.7%)	17 (7.0%)	0.004	
	WT	209 (84.3%)	227 (93.0%)		
Age (median [IQR])		62.00 (56.00, 66.00)	61.00 (56.00, 66.00)	0.143	nonnorm
PSA (ng/ml) (median [IQR])		0.10 (0.03, 0.26)	0.10 (0.03, 0.10)	0.105	nonnorm

Note: "exact" means that the statistical method was Fisher's exact test. "nonnorm" means a non-normal distribution and a Wilcoxon rank sum test was used for the statistical analysis.